Epidemiology of symptomatic drug-induced long QT syndrome and torsade de pointes in Germany
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
AIMS: Drug-induced long QT syndrome (diLQTS) leading to Torsade de Pointes (TdP) is a potentially lethal condition, which has led to several post-marketing drug withdrawals in the past decade. The true incidence of diLQTS/TdP is largely unknown. One explanation is under-reporting of this potentially life-threatening adverse event by physicians and other medical staff to pharmacovigilance agencies. To gain more insight into the incidence of diLQTS and TdP, the Berlin Pharmacovigilance Center (PVZ-FAKOS) has actively and prospectively identified patients who developed this particular type of drug-induced adverse event. Here, the basic characteristics of the affected patients are summarized and suspected drugs are discussed. Furthermore, an extrapolation of the Berlin incidence rates to the German Standard Population is presented. METHODS AND RESULTS: Using a Berlin-wide network of 51 collaborating hospitals (>180 clinical departments), adult patients presenting with long QT syndrome (LQTS/TdP) between 2008 and 2011 were identified by active surveillance of these hospitals. Drug exposures as well as other possible risk factors were obtained from the patient's files and in a face-to-face interview with the patient. One-hundred and seventy patients of possible LQTS/TdP were reported to the Pharmacovigilance Center of whom 58 cases were confirmed in a thorough validation process. The majority (66%) of these cases were female and 60% had developed LQTS/TdP in the outpatient setting. Thirty-five (60%) of 58 confirmed cases were assessed as drug-related based on a standardized causality assessment applying the criteria of the World Health Organization. Drugs assessed as related in more than two cases were metoclopramide, amiodarone, melperone, citalopram, and levomethadone. The age-standardized incidence of diLQTS/TdP in Berlin was estimated to be 2.5 per million per year for males and 4.0 per million per year for females. CONCLUSION: While European annual reporting rates based on spontaneous reports suggest an annual diLQTS/TdP incidence of 0.26 per million in Germany, we estimated a considerably higher incidence of diLQTS/TdP in an active surveillance approach. Further measures are warranted to better sensitize physicians against this potentially life-threatening drug-induced adverse event.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug-induced prolongation of the QT interval
Roden, D. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmra032426 · Cited by 1,965
Laverty, H., Benson, C., Cartwright, E., Cross, M., Garland, C., Hammond, T., Holloway, C., McMahon, N., Milligan, J., Park, B., et al. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01255.x · Cited by 363
Cited by
Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association
Benjamin, E. J., Blaha, M. J., Chiuve, S. E., Cushman, M., Das, S. R., Deo, R., de Ferranti, S. D., Floyd, J., Fornage, M., Gillespie, C., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000485 · Cited by 12,591
Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
Virani, S. S., Alonso, A., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Delling, F. N., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000757 · Cited by 9,175
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Das, S. R., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000659 · Cited by 9,036
Heart disease and stroke statistics-2018 update: a report from the american heart association
Benjamin, E. J., Virani, S. S., Callaway, C. W., Chamberlain, A. M., Chang, A. R., Cheng, S., Chiuve, S. E., Cushman, M., Delling, F. N., Deo, R., et al. (2018) · Circulation · doi:10.1161/cir.0000000000000558 · Cited by 7,146
Heart Disease and Stroke Statistics—2016 Update: A Report From the American Heart Association
Mozaffarian, D., Benjamin, E. J., Go, A. S., Arnett, D. K., Blaha, M. J., Cushman, M., Das, S. R., de Ferranti, S., Després, J.-P., Fullerton, H. J., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000350 · Cited by 6,596
Priori, S. G., Blomström-Lundqvist, C., Mazzanti, A., Blom, N., Borggrefe, M., Camm, J., Elliott, P. M., Fitzsimons, D., Hatala, R., Hindricks, G., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv316 · Cited by 3,893
(2015) · Europace · doi:10.1093/europace/euv319 · Cited by 1,592
Topjian, A. A., Raymond, T. T., Atkins, D., Chan, M., Duff, J. P., Joyner, B. L., Lasa, J. J., Lavonas, E. J., Levy, A., Mahgoub, M., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000901 · Cited by 1,258
Drug-Induced Arrhythmias: A Scientific Statement From the American Heart Association
Tisdale, J. E., Chung, M. K., Campbell, K. B., Hammadah, M., Joglar, J. A., Leclerc, J., Rajagopalan, B., & On behalf of the American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology and Council on Cardiovascular and Stroke Nursing (2020) · Circulation · doi:10.1161/cir.0000000000000905 · Cited by 399
Saleh, M., Gabriels, J., Chang, D., Soo Kim, B., Mansoor, A., Mahmood, E., Makker, P., Ismail, H., Goldner, B., Willner, J., et al. (2020) · Circulation: Arrhythmia and Electrophysiology · doi:10.1161/circep.120.008662 · Cited by 340
Schwartz, P. J., & Woosley, R. L. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.12.063 · Cited by 328
Antidepressants for the treatment of depression in people with cancer
Ostuzzi, G., Matcham, F., Dauchy, S., Barbui, C., & Hotopf, M. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011006.pub3 · Cited by 158
Antidepressants for the treatment of depression in people with cancer
Vita, G., Compri, B., Matcham, F., Barbui, C., & Ostuzzi, G. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011006.pub4 · Cited by 73
Recent developments in using mechanistic cardiac modelling for drug safety evaluation
Davies, M. R., Wang, K., Mirams, G. R., Caruso, A., Noble, D., Walz, A., Lavé, T., Schuler, F., Singer, T., & Polonchuk, L. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.02.003 · Cited by 66
“This is emphasised in a study [74] that shows that, although TdP is an exemplar adverse event, a incidence of TdP from their observational study and a lack of ICD-10 coding options mean that some important drug-induced arrhythmia events could be missed or recorded as other ventricular fibrillation…”
BackgroundMethodBerger, F. A., van der Sijs, H., Becker, M. L., van Gelder, T., & van den Bemt, P. M. L. A. (2020) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-020-01181-3 · Cited by 38
Ali, Z., Ismail, M., Khan, F., & Sajid, H. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1846717 · Cited by 21
“the post-marketing withdrawal of many drugs [2,9] and since 1989, 14 clinically important drugs have been withdrawn from the market [9].”
BackgroundDrug-induced long-QT syndrome and torsade de pointes: an underrated problem?
Rao, P., & Kowey, P. R. (2014) · Europace · doi:10.1093/europace/eut331 · Cited by 4
“Indeed, one of the most frequent causes of restrictive drug labelling or withdrawal has been prolongation of the QTc interval associated with fatal cardiac arrhythmias.1 While our increasing understanding of the molecular and cellular changes that are induced by drugs that produce this phenomenon, and our ability to a…”
Background
Metadata
- Authors
- Sarganas, G., Garbe, E., Klimpel, A., Hering, R. C., Bronder, E., & Haverkamp, W.
- Venue
- Europace
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-07-05
- Volume
- 16
- Issue
- 1
- Pages
- 101-108
- ISSN
- 1099-5129 (ISSN-L)
- 1532-2092
- OpenAlex
- W2120346674
- Cited by
- 156
- References
- 2
- FWCI
- 6.78
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.